Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01887418 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Testosterone Enanthate
A Phase 1 study, sponsored by Antares Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT01887418: Completed Phase 1 study, sponsored by Antares Pharma.
NCT01887418 is a Phase 1 study that has completed, run by Antares Pharma. The registered enrollment target is 39 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01887418, a Phase 1 study, has completed, sponsored by Antares Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
Relative Bioavailability and Safety comparison of 3 formulations of Testosterone Enanthate.
Primary Outcome
The area under the curve from time zero to last quantifiable concentration \[AUC (0-t)\] of TE administered by SC injection once weekly at doses of 50 mg and 100 mg via the QST
Interventions
- DRUG QuickShot™ - 50 mg Treatment B
- DRUG QuickShot™ - 100 mg Treatment A
- DRUG Delatestryl 200 mg IM Treatment C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
What the finished NCT01887418 record still lists
NCT01887418 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 3 interventions - of which QuickShot™ - 50 mg Treatment B is the first listed.
NCT01887418 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01887418 about?
NCT01887418 is a clinical study titled "Pharmacokinetic Study of Testosterone Enanthate". Relative Bioavailability and Safety comparison of 3 formulations of Testosterone Enanthate.
What is the current status of trial NCT01887418?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2013-09. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01887418?
The interventions under investigation include: QuickShot™ - 50 mg Treatment B (DRUG), QuickShot™ - 100 mg Treatment A (DRUG), Delatestryl 200 mg IM Treatment C (DRUG).
Who is sponsoring clinical trial NCT01887418?
This trial is sponsored by Antares Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01887418's enrollment target sits among peer trials
39 1191st of 2000 higher than 804 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia